glutamic acid has been researched along with Granulocytic Leukemia, Chronic in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheong, JW; Choi, JR; Kim, SJ; Lee, KA; Lee, KW; Park, TS; Song, J; Song, S; Suh, B | 1 |
| Dubey, KD; Ojha, RP | 1 |
| Bassan, R; Bussini, A; Castagnetti, F; Gnani, A; Intermesoli, T; Rosti, G; Soverini, S; Spinelli, O | 1 |
3 other study(ies) available for glutamic acid and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
Concomitant t(3;3)(q21;q26), trisomy 19, and E255V mutation associated with imatinib mesylate resistance in chronic myelogenous leukemia.
Topics: Amino Acid Substitution; Antineoplastic Agents; Base Sequence; Benzamides; Chromosomes, Human, Pair 19; Chromosomes, Human, Pair 3; Drug Resistance, Neoplasm; Female; Glutamic Acid; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Mutation, Missense; Piperazines; Prognosis; Pyrimidines; Translocation, Genetic; Trisomy; Valine | 2009 |
Conformational flexibility, binding energy, role of salt bridge and alanine-mutagenesis for c-Abl kinase complex.
Topics: Alanine; Benzamides; Binding Sites; Glutamic Acid; Humans; Hydrogen Bonding; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Ligands; Lysine; Molecular Dynamics Simulation; Mutagenesis; Piperazines; Protein Binding; Protein Conformation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Salts; Thermodynamics | 2012 |
Durable molecular response despite F317L and E255K mutations: Successful treatment of chronic myeloid leukemia with sequential imatinib, nilotinib and dasatinib.
Topics: Adult; Amino Acid Substitution; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Pharmacological; Biomarkers, Tumor; Dasatinib; Female; Fusion Proteins, bcr-abl; Glutamic Acid; Humans; Imatinib Mesylate; Leucine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lysine; Mutation, Missense; Phenylalanine; Piperazines; Polymorphism, Single Nucleotide; Pyrimidines; Remission Induction; Thiazoles; Time Factors; Treatment Outcome | 2012 |